IL10 and neoplasm: In our case, this might be explained by the fact that the NB-PDT treated tumor supernatants present TLR4 agonist activity (Figure S5), in agreement with the increase of HSP70 and HMGB1 that are TLR4 agonists themselves and can trigger IL-10 release [27].